CXCR2 antagonism has also demonstrated significant antitumor activity in a preclinical model for colon cancer (Ning et al., 2012) and slowed growth and antagonized metastasis in a recombinant mouse model of pancreatic adenocarcinoma (Shi et al., 2014). Here, CXCR2 is linked to malignant colon neoplasm.